Malaria prevention in the pregnant traveller: a review
Standard
Malaria prevention in the pregnant traveller: a review. / Roggelin, Louise; Cramer, Jakob P.
In: TRAVEL MED INFECT DI, Vol. 12, No. 3, 13.05.2014, p. 229-36.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Malaria prevention in the pregnant traveller: a review
AU - Roggelin, Louise
AU - Cramer, Jakob P
N1 - Copyright © 2014 Elsevier Ltd. All rights reserved.
PY - 2014/5/13
Y1 - 2014/5/13
N2 - Malaria is still a major threat to health in tropical regions. Particular attention should be directed to malaria prevention in infants and pregnant women as they are at high risk for plasmodial infection and complicated malaria. In this review, we summarize and discuss current evidence on malaria prevention in pregnant travellers. As neither anti-mosquito measures nor anti-malarial drugs have been proven to be unequivocally safe or toxic in pregnant women, the individual risk assessment should take into account the risk of transmission at the destination, the benefit of travelling despite being pregnant as well as the individual risk perception. All three factors may differ in various groups of travellers like tourist travellers, expatriate travellers as well as those visiting friends and relatives. For pregnant women, mefloquine appears to be the drug of choice for prophylaxis and stand by-therapy if no contraindications exist - despite recent renewed warnings related to prolonged side effects. In areas with high resistance against mefloquine or in women with contraindications to mefloquine, atovaquone-proguanil or artemether-lumefantrine should be considered as an option for stand-by emergency therapy. Nevertheless, evidence on the safety of anti-malarials especially during the first trimester is still insufficient.
AB - Malaria is still a major threat to health in tropical regions. Particular attention should be directed to malaria prevention in infants and pregnant women as they are at high risk for plasmodial infection and complicated malaria. In this review, we summarize and discuss current evidence on malaria prevention in pregnant travellers. As neither anti-mosquito measures nor anti-malarial drugs have been proven to be unequivocally safe or toxic in pregnant women, the individual risk assessment should take into account the risk of transmission at the destination, the benefit of travelling despite being pregnant as well as the individual risk perception. All three factors may differ in various groups of travellers like tourist travellers, expatriate travellers as well as those visiting friends and relatives. For pregnant women, mefloquine appears to be the drug of choice for prophylaxis and stand by-therapy if no contraindications exist - despite recent renewed warnings related to prolonged side effects. In areas with high resistance against mefloquine or in women with contraindications to mefloquine, atovaquone-proguanil or artemether-lumefantrine should be considered as an option for stand-by emergency therapy. Nevertheless, evidence on the safety of anti-malarials especially during the first trimester is still insufficient.
KW - Antimalarials
KW - Drug Resistance
KW - Female
KW - Humans
KW - Infant
KW - Malaria
KW - Mosquito Control
KW - Pregnancy
KW - Preventive Health Services
KW - Risk Assessment
KW - Travel
U2 - 10.1016/j.tmaid.2014.04.007
DO - 10.1016/j.tmaid.2014.04.007
M3 - SCORING: Journal article
C2 - 24813714
VL - 12
SP - 229
EP - 236
JO - TRAVEL MED INFECT DI
JF - TRAVEL MED INFECT DI
SN - 1477-8939
IS - 3
ER -
